News
Akeso enrols first patient in phase Ia trial for AK146D1, a bispecific ADC targeting Trop2 and Nectin4: Hong Kong Monday, July 7, 2025, 18:00 Hrs [IST] Akeso, Inc., a leading biop ...
WatchTowr, a company known for publishing proof-of-concept (PoC) exploits, initially stated it would refrain from releasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback